tedizolid phosphate - Profile

What are the generic sources for tedizolid phosphate and what is the scope of patent protection?

Tedizolid phosphate is the generic ingredient in one branded drug marketed by Cubist Pharms Llc and is included in two NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tedizolid phosphate has seventy-nine patent family members in thirty-nine countries.

Summary for tedizolid phosphate

International Patents:	79
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	2

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for tedizolid phosphate

Dosage:

POWDER;INTRAVENOUS

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for tedizolid phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes			Y	Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes			Y	Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes			Y	Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes			Y	Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes			Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes				Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes			Y

EU/EMA Drug Approvals for tedizolid phosphate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Sivextro	tedizolid phosphate	EMEA/H/C/002846Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and adolescents 12 years of age and older.	Authorised	no	no	no	2015-03-23

International Patents for tedizolid phosphate

Country	Patent Number	Title	Estimated Expiration
New Zealand	712289	Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
New Zealand	594408	Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Cyprus	1112445
Russian Federation	2655928	Кристаллические частицы для приготовления твердых лекарственных форм для лечения бактериальных инфекций, реакционная смесь, содержащая такие частицы, и фармацевтическая композиция для лечения бактериальных инфекций (CRYSTALLINE PARTICLES FOR PREPARATION OF SOLID DOSAGE FORMS FOR TREATMENT OF BACTERIAL INFECTIONS, REACTION MIXTURE CONTAINING SUCH PARTICLES, AND PHARMACEUTICAL COMPOSITION FOR TREATING BACTERIAL INFECTIONS)
Singapore	173497
Colombia	6620071	Forma cristalina del fosfato de dihidrogeno r)-3-(4-(2-(2-metiltetrazol-5-il)piridin-5-il)-3-fluorofenil)-5-hidroximetil oxazolidin-2-ona
Japan	2007514737

Supplementary Protection Certificates for tedizolid phosphate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1699784	92834	Luxembourg		PRODUCT NAME: TEDIZOLIDE, OPTIONNELLEMENT SOUS LA FORME D UN ESTER, EN PARTICULIER UN PHOSPHATE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150325
1699784	243 50021-2015	Slovakia		PRODUCT NAME: TEDIZOLIDFOSFAT; REGISTRATION NO/DATE: EU/1/15/991/001 - EU/1/15/991/003 20150325
1699784	PA2015032,C1699784	Lithuania		PRODUCT NAME: TEDIZOLIDAS, PASIRINKTINAI ESTERIO PAVIDALU, YPAC FOSFATO ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/991 20150323
1699784	1590047-5	Sweden		PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/991 20150325
1699784	PA2015032	Lithuania		PRODUCT NAME: TEDIZOLIDO FOSFATAS; REGISTRATION NO/DATE: EU/1/15/991 20150323
1699784	CR 2015 00048	Denmark		PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325
1699784	C01699784/01	Switzerland		PRODUCT NAME: TEDIZOLID; REGISTRATION NO/DATE: SWISSMEDIC 65270 05.01.2016

Investment Scenario, Market Dynamics, and Financial Trajectory for Tedizolid Phosphate

Last updated: February 3, 2026

Executive Summary

Tedizolid phosphate (trade name: Sivextro) is a second-generation oxazolidinone antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Despite its relatively recent market entry in 2014, the drug's niche positioning, evolving resistance profiles, and strategic positioning against competitors significantly influence its long-term commercial prospects. This report systematically analyzes the investment landscape, market forces, and projected financial trajectory of tedizolid phosphate, providing critical insights for stakeholders and investors.

---

1. Market Overview and Current Status of Tedizolid Phosphate

1.1. Product Profile and Approvals

Attribute	Details
Brand Name	Sivextro
Approved Indications	ABSSSI (FDA, 2014); also studied for pneumonia, bloodstream infections (not approved in all markets)
Dosage Form	Intravenous and oral formulations
Approval Authorities	FDA (2014), EMA (2017)
Competitive Position	Second-generation oxazolidinone, positioned as an alternative to linezolid for resistant infections

1.2. Selling Points and Differentiators

• Potency and Spectrum: Effective against gram-positive pathogens including MRSA, VRE.
• Pharmacokinetics: Favorable oral bioavailability and fewer drug interactions compared to linezolid.
• Resistance Profile: Less associated with hematological adverse effects.

1.3. Revenue Performance

Year	Global Sales (USD million)	Annual Growth	Market Share in Antibiotics Segment
2014	20	—	0.5%
2018	150	50% CAGR	2.3%
2022	~250	25% CAGR	3.5%

Note: Steady growth driven by expanding indications and geographic reach.

---

2. Market Dynamics

2.1. Key Drivers

• Rising Antimicrobial Resistance (AMR): Increasing cases of MRSA and VRE bolster demand for advanced antibiotics like tedizolid.
• Preferred Over Linezolid: Lower toxicity profile and fewer contraindications favor tedizolid in specific patient populations.
• Oral Formulation Advantage: Easier outpatient management reduces hospitalization costs, increasing adoption.

2.2. Constraints and Challenges

Constraint	Impact	Mitigation Strategies
Limited Indications	Only approved for ABSSSI; limits market potential	Broadening clinical trials for pneumonia, other infections
Competition from Linezolid & Others	Established market presence, brand loyalty	Demonstrating superior safety/effectiveness
Pricing and Reimbursement Trends	Pricing pressures in mature markets	Value-based pricing strategies
Resistance Development	Potential emergence of resistance reducing efficacy	Continuous surveillance, combination therapy studies

2.3. Competitive Landscape

Competitor	Drug Name	Market Share (2022)	Key Differentiator	Regulatory Status
Pfizer	Zithromax, Zyvox	55% (oxazolidinones)	Established in hospital settings	FDA, EMA approved
Merck	Recarbrio	Recently launched	Broader spectrum, combination therapies	FDA approval (2020)
Pfizer/Next-gen	Tedizolid (Sivextro)	3.5%	Preference in resistant infections	Approved in US/Europe

2.4. Emerging Trends

• Expanded Indications: Trials for pneumonia, bloodstream infections.
• Formulation Innovations: Development of sustained-release formulations.
• Regional Expansion: Focus on Asia-Pacific markets with rising infectious disease burdens.

---

3. Financial Trajectory Projections

3.1. Revenue Forecasting (2023-2030)

Year	Projected Sales (USD million)	Growth Rate	Assumptions
2023	300	20%	Increased adoption, new indications, geographic expansion
2025	500	25%	Successful launch of pipeline indications, market penetration
2027	750	22%	Market saturation, competitive positioning
2030	1,000	20%	Mature market with stable demand

Notes: Assumes steady approval of additional indications, sustained R&D investment, partnerships for regional expansion.

3.2. Cost Structure and Profitability

Cost Item	Estimated Percentage of Revenue	Rationale
R&D Expenses	10-15%	Clinical trials, formulation development
Manufacturing & Supply	5-8%	Scale-up, quality control
Marketing & Sales	15-20%	Physician education, KOL engagement
Administrative & Overhead	5-7%	Corporate operations

Profit Margin Estimation	Range	Notes
Operating Margin	20-30%	Based on economies of scale, mature pipelines
Net Profit Margin	15-20%	After taxes and interest

3.3. Investment Considerations

• Pipeline Expansion: Clinical trials for pneumonia, bloodstream infections could significantly enhance revenue.
• Pricing & Reimbursement Trends: Depending on payer policies, margins could fluctuate.
• Patent Expiry & Generics: Venturing into new indications and formulations is essential for long-term profitability.

---

4. Comparative Analysis: Tedizolid Phosphate vs. Competitors

Feature	Tedizolid Phosphate	Linezolid (Zyvox)	Others (e.g., Dalbavancin)
Approval Year	2014	2000	Varies
Indications (mainly ABSSSI)	Yes	Yes	Selective
Oral Bioavailability	>80%	~100%	Varied
Hematologic Side Effects	Lower	Higher	N/A
Resistance Development Potential	Lower	Higher	N/A

---

5. Policy and Regulatory Environment

• FDA & EMA Approvals: Established; ongoing post-market surveillance essential.
• Pricing Policies: Shift toward value-based models; influence market penetration.
• Antimicrobial Stewardship: Impacts prescribing trends for new antibiotics.

---

Key Takeaways

• Growth Outlook: Tedizolid phosphate exhibits promising growth potential, driven by resistance challenges and formulation advantages. Projected sales could reach USD 1 billion by 2030 with strategic expansion.
• Market Position: As a niche but differentiated antibiotic, it faces competition from long-established drugs like linezolid. Differentiation through safety, efficacy, and indication expansion is crucial.
• Investment Priority: Focus on clinical trial success for new indications, regional expansion especially in emerging markets, and partnership strategies to secure patent protections and stratify pricing.
• Risks: Resistance evolution, regulatory delays, pricing pressures, and patent cliffs pose ongoing challenges.
• Strategic Recommendations: Invest in pipeline development, tailorable marketing strategies, and adaptive positioning aligned with antimicrobial stewardship policies.

---

FAQs

Q1. What are the primary benefits of tedizolid phosphate compared to linezolid?
Tedizolid has a lower propensity for hematologic side effects, improved dosing regimens (once daily), and fewer drug interactions, making it preferable for certain patient populations.

Q2. What are the main barriers to the expansion of tedizolid’s market share?
Limited approved indications beyond ABSSSI, competition from established antibiotics (e.g., linezolid), and pricing/reimbursement constraints hamper expansion.

Q3. Are there upcoming clinical trials that could broaden tedizolid’s approved uses?
Yes. Multiple phase II and III trials evaluate tedizolid for pneumonia, bacteremia, and other resistant infections. Successful outcomes could catalyze market growth.

Q4. How does regional market potential vary for tedizolid?
Asia-Pacific and Latin American markets present growing demand due to rising antimicrobial resistance, with regulatory pathways often favoring accelerated approvals.

Q5. What is the patent expiration timeline for tedizolid?
Patent protections are projected to expire around 2030, depending on jurisdiction and any extensions or supplementary protections. Competition from generics post-expiration could significantly impact pricing and sales.

---

References

1. US Food and Drug Administration (FDA). (2014). Sivextro (tedizolid phosphate) NDA approval.
2. European Medicines Agency (EMA). (2017). Sivextro approval in Europe.
3. IQVIA. (2022). Global Antibiotics Market Report.
4. ClinicalTrials.gov. (2023). Ongoing clinical trials involving tedizolid.
5. Johns Hopkins Medicine. (2022). Antimicrobial resistance trends.